Evolocumab and Clinical Outcomes in Patients with Cardiovascular DiseaseMarc S. Sabatine, Terje R. Pedersen, Robert P. Giugliano et al.|New England Journal of Medicine|2017Cited by 6k
Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trialsJane Armitage, Martin Landray, Colin Baigent et al.|The Lancet|2019Cited by 785
Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery DiseaseMarc P. Bonaca, Marc S. Sabatine, Patrice Nault et al.|Circulation|2017Cited by 754
Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trialMarc S. Sabatine, Terje R. Pedersen, Lawrence A. Leiter et al.|The Lancet Diabetes & Endocrinology|2017Cited by 595
Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trialsRory Collins, William G. Herrington, Jonathan Emberson et al.|The Lancet Diabetes & Endocrinology|2016Cited by 338